The Filing Desk

Zhengye Biotechnology vs Zymeworks

Zhengye Biotechnology ZYBT · Zymeworks ZYME · Pharmaceuticals

Zhengye Biotechnology reported revenue of CN¥116 million in fiscal 2025, and Zymeworks $106 million in fiscal 2025, in different currencies. Zhengye Biotechnology's revenue fell 37.6% in its latest year, and Zymeworks' grew 38.9%. Zhengye Biotechnology had an operating margin of -60.6%, against -87.3% at Zymeworks. Free cash flow was CN¥12 million at Zhengye Biotechnology and −$35 million at Zymeworks.

Side by side

Zhengye BiotechnologyZymeworks
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
RevenueCN¥116M$106M
Revenue growth−37.6%38.9%
Revenue growth a year, last 5 years—22.1%
Gross margin20.5%—
Operating margin−60.6%−87.3%
Net margin−60.0%−76.6%
Free cash flowCN¥12M−$35M
Free cash flow margin10.6%−32.6%
Return on capital−14.9%—
Net debt to EBITDA——
Dividends and buybacksCN¥0M$42M
Change in diluted share count3.7%−0.6%
Last close$1.52$26.86
P/E at the last close—51.7×
Insider trades, last 12 months—sold $6.1 million
Piotroski F-score3 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
In each company's own currency, fiscal years
Zhengye BiotechnologyZymeworks
Operating margin
Percent of revenue
Zhengye BiotechnologyZymeworks
Free cash flow
In each company's own currency. Cash from operations minus capital expenditure.
Zhengye BiotechnologyZymeworks

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Zhengye Biotechnology and Zymeworks pages.